Innovative Medicine

Innovative Medicine

July 15, 2011

Janssen Pharmaceuticals, Inc. Announces Definitive Agreement To Divest Ortho Dermatologics Division

Innovative Medicine

July 8, 2011

Crucell Discovers Important New Antibody Against Influenza A

Innovative Medicine

July 7, 2011

Janssen Pharmaceutica NV Completes Divestiture Of Animal Health Business To Elanco, A Division Of Eli Lilly And Company

Innovative Medicine

July 1, 2011

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery

XARELTO® is the only new oral anticoagulant with FDA approval in this indication

Innovative Medicine

June 28, 2011

Tibotec Pharmaceuticals Announces Agreement With Gilead Sciences To Develop And Commercialize A New Fixed-Dose Combination Of Prezista® And Cobicistat

Innovative Medicine

June 22, 2011

Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies

Unified Janssen companies around the world continue commitment to patients and to addressing unmet medical needs

Innovative Medicine

June 17, 2011

Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets

Innovative Medicine

June 6, 2011

DACOGEN® (decitabine) showed an overall survival advantage compared with the accepted standard therapies in older patients with newly diagnosed de novo or secondary acute myeloid leukemia

Data from DACO-016 study at 2011 American Society of Clinical Oncology Annual Meeting

Innovative Medicine

June 4, 2011

Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells As Potential Biomarker for Metastatic Prostate Cancer Clinical Trials

Study utilized Veridex’s CELLSEARCH® CTC Test, the only regulatory-cleared in vitro diagnostic test to capture and count CTCs